Cardiol Therapeutics Inc.
NASDAQ: CRDL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- David G. Elsley
- Employees
- 18
- Headquarters
- Oakville, Canada
- IPO year
- 2019
- Market cap
- $118.7M
- Website
- https://www.cardiolrx.com
Loading CRDL…
Loading profile data…Frequently asked questions about CRDL
What does Cardiol Therapeutics Inc. (CRDL) do?
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial ass...
Where does CRDL trade?
Cardiol Therapeutics Inc. (CRDL) trades on the NASDAQ Capital Market.
What sector is CRDL in?
Cardiol Therapeutics Inc. (CRDL) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Cardiol Therapeutics Inc.?
David G. Elsley is the chief executive officer of Cardiol Therapeutics Inc. (CRDL).
Where is Cardiol Therapeutics Inc. headquartered?
Cardiol Therapeutics Inc. is headquartered in Canada.
Does CRDL pay a dividend?
Cardiol Therapeutics Inc. (CRDL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRDL go public?
Cardiol Therapeutics Inc. (CRDL) completed its initial public offering in 2019.